Related references
Note: Only part of the references are listed.Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
Eric A. F. Simoes et al.
LANCET CHILD & ADOLESCENT HEALTH (2023)
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
B. Kampmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Laura L. Hammitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
Joseph Domachowske et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
Susanna Esposito et al.
FRONTIERS IN IMMUNOLOGY (2022)
RSV: UK to examine whether to offer monoclonal antibody routinely to all babies
Jacqui Wise
BMJ-BRITISH MEDICAL JOURNAL (2022)
Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009-2019: A Study of the National (Nationwide) Inpatient Sample
Mina Suh et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life in the United States: Systematic Literature Review and Analysis( )
Elizabeth L. Glaser et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis
Diana M. Bowser et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
The assessment of future RSV immunizations: How to protect all infants?
Louis Bont et al.
FRONTIERS IN PEDIATRICS (2022)
Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups
Zhe Zheng et al.
PNEUMONIA (2022)
Ethics of Vaccination in Childhood-A Framework Based on the Four Principles of Biomedical Ethics
Meta Rus et al.
VACCINES (2021)
Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study
You Li et al.
LANCET INFECTIOUS DISEASES (2021)
Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities
Jintanat Ananworanich et al.
VACCINES (2021)
Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China
Yanbing Zeng et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Two new medicines may curb serious respiratory disease in infants
Jon Cohen
SCIENCE (2020)
Scientific and Ethical Principles Underlying Recommendations From the Advisory Committee on Immunization Practices for COVID-19 Vaccination Implementation
Beth P. Bell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15
Carmen S. Arriola et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review
Stephen Mac et al.
PEDIATRICS (2019)
Respiratory Syncytial Virus-Associated Outpatient Visits Among Children Younger Than 24 Months
Joana Y. Lively et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2019)
Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies
Barnaby Young et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Respiratory Syncytial Virus Seasonality - United States, 2014-2017
Erica Billig Rose et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
The Economic Burden of Asthma in the United States, 2008-2013
Tursynbek Nurmagambetov et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2018)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Ting Shi et al.
LANCET (2017)
Effectiveness of Palivizumab in High-risk Infants and Children A Propensity Score Weighted Regression Analysis
Evan J. Anderson et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
Rohan C. Parikh et al.
INFECTIOUS DISEASES AND THERAPY (2017)
Respiratory Syncytial Virus-Associated Hospitalizations Among Children Less Than 24 Months of Age
Caroline Breese et al.
PEDIATRICS (2013)
Monoclonal antibodies: magic bullets with a hefty price tag
Allen F. Shaughnessy
BRITISH MEDICAL JOURNAL (2012)
Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants
Nianwen Shi et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Harish Nair et al.
LANCET (2010)
Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systemic review and meta-analysis
CF Lee et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants
S Leader et al.
VALUE IN HEALTH (2003)
Imperfect vaccines and the evolution of pathogen virulence
S Gandon et al.
NATURE (2001)
Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid
TG Boyce et al.
JOURNAL OF PEDIATRICS (2000)